EPO Biomarkers Market size and Key Trends in terms of volume and value 2016-2026
Erythropoietin is special type of protein biomarker, also known as a growth factor. It acts by the stimulating the bone marrow to manufacture red blood cells. There are five different types of erythropoietin biomarkers such as epoetin alfa, epoetin beta, epoetin zeta, epoetin theta and darbepoetin alfa. Erythropoietin is mostly administered subcutaneously as an alternative to iron supplements. Erythropoietin used in human beings is also known as recombinant human erythropoietin (rHuEPO). Commercially available rHuEPO has the same 165 amino acid sequence as available in naturally occurring hormone but the level of glycosylation in rHuEPO depends on the testing method used. Growing global incidence of renal diseases and cancers is expected to create a marked increase in use of EPO biomarkers.
Erythropoietin is special type of protein biomarker, also known as a growth factor. It acts by the stimulating the bone marrow to manufacture red blood cells. There are five different types of erythropoietin biomarkers such as epoetin alfa, epoetin beta, epoetin zeta, epoetin theta and darbepoetin alfa. Erythropoietin is mostly administered subcutaneously as an alternative to iron supplements. Erythropoietin used in human beings is also known as recombinant human erythropoietin (rHuEPO). Commercially available rHuEPO has the same 165 amino acid sequence as available in naturally occurring hormone but the level of glycosylation in rHuEPO depends on the testing method used. Growing global incidence of renal diseases and cancers is expected to create a marked increase in use of EPO biomarkers.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Report Description<br />
This could also hamper progress <strong>of</strong> ongo<strong>in</strong>g cl<strong>in</strong>ical trials <strong>and</strong> proper stratification <strong>of</strong><br />
patients.<br />
Request free sample Report: http://www.futuremarket<strong>in</strong>sights.com/reports/sample/repgb-1382<br />
<strong>EPO</strong> <strong>Biomarkers</strong> <strong>Market</strong>: Segmentation<br />
<strong>EPO</strong> <strong>Biomarkers</strong> is classified on the basis <strong>of</strong> biomarker, <strong>in</strong>dication, test<strong>in</strong>g method <strong>and</strong><br />
end user type:<br />
Based on biomarker type, the global <strong>EPO</strong> <strong>Biomarkers</strong> is segmented <strong>in</strong>to the follow<strong>in</strong>g:<br />
• Recomb<strong>in</strong>ant human erythropoiet<strong>in</strong><br />
• Erythropoiet<strong>in</strong> alfa<br />
• Erythropoiet<strong>in</strong> beta<br />
• Erythropoiet<strong>in</strong> zeta<br />
• Erythropoiet<strong>in</strong> theta<br />
• Darbepoiet<strong>in</strong> alfa<br />
Based on <strong>in</strong>dication, the global <strong>EPO</strong> <strong>Biomarkers</strong> is segmented <strong>in</strong>to follow<strong>in</strong>g:<br />
• End stage renal disorder
Change language